Lomitapide
- Generic Name
- Lomitapide
- Brand Names
- Juxtapid, Lojuxta
- Drug Type
- Small Molecule
- Chemical Formula
- C39H37F6N3O2
- CAS Number
- 182431-12-5
- Unique Ingredient Identifier
- 82KUB0583F
Overview
Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R).
Background
Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R).
Indication
用于纯合子家族性高胆固醇血症以及高胆固醇血症。
Associated Conditions
- Homozygous Familial Hypercholesterolaemia (HoFH)
Clinical Trials
FDA Approved Products
Juxtapid
Manufacturer:Chiesi USA, Inc.
Route:ORAL
Strength:5 mg in 1 1
Approved: 2024/01/25
NDC:10122-405
Juxtapid
Manufacturer:Amryt Pharmaceuticals DAC
Route:ORAL
Strength:20 mg in 1 1
Approved: 2020/09/28
NDC:76431-120
Juxtapid
Manufacturer:Amryt Pharmaceuticals DAC
Route:ORAL
Strength:5 mg in 1 1
Approved: 2020/09/28
NDC:76431-105
Juxtapid
Manufacturer:Chiesi USA, Inc.
Route:ORAL
Strength:10 mg in 1 1
Approved: 2024/01/25
NDC:10122-410
Juxtapid
Manufacturer:Amryt Pharmaceuticals DAC
Route:ORAL
Strength:10 mg in 1 1
Approved: 2020/09/28
NDC:76431-110
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath